39results about How to "Broad-spectrum antiviral activity" patented technology

The invention discloses applications of dihydromyricetin in preparation of anti-influenza virus drugs, wherein influenza virus is influenza A virus, preferably H1N1, H3N2, H5N1, H7N1, H7N2, H7N3, H7N7, H7N9, H9N2 or H10N8. According to the present invention, the anti-influenza A virus action mechanism of the dihydromyricetin is that the activity of the ribonucleoprotein complex vRNP is inhibited by binding the dihydromyricetin to the PB2cap protein so as to prepare the drugs for prevention and treatment of influenza, wherein the binding loci of the dihydromyricetin and the PB2cap protein are site-432 histidine (His432), site-357 histidine (His357), site-404 phenylalanine (Phe404), site-323 Phenylalanine (Phe323), site-361 glutamic acid (Glu361), site-376 lysine (Lys376), site-363 phenylalanine (Phe363), and site-429 asparagine (Asn429).

The invention discloses a fatty acid complex. The fatty acid complex comprises the following components in parts by weight: 2.2-3 parts of mixed fatty acid, 16-40 parts of a surfactant and 40-60 partsof auxiliary acid, wherein the mixed fatty acid is a mixture of octanoic acid, nonoic acid and capric acid; the auxiliary acid is lauric acid or a mixture of the lauric acid and citric acid. The fatty acid complex has broad-spectrum bactericidal and antiviral activity, can kill polioviruses, foot-and-mouth disease viruses, porcine reproductive and respiratory syndrome viruses and avian influenzaviruses, has the staphylococcus aureus and escherichia coli killing rate as high as 99.99999%; the fatty acid complex has excellent storage stability under a diluted condition, is applied to a food disinfectant, has an excellent food preserving function, is free of cleaning during disinfection, free of metal corrosion, practically non-toxic and non-irritant to skin, and is unlikely to volatilize;the fatty acid complex has acidic pH and a light coconut scent, disinfecting cleaning sewage does not pollute the environment, and the fatty acid complex can be reused in some disinfecting scenes.

The invention discloses application of dendrobine in preparation of anti-influenza virus medicines. The influenza virus is influenza a virus, preferably H1N1, H3N2, H5N1, H7N1, H7N2, H7N3, H7N7, H7N9, H9N2 or H10N8. The dendrobine can be used for preparing medicines capable of inhibiting replication of influenza a virus in host cells, and is capable of inhibiting denucleation of a virus ribonucleoprotein complex vRNP or activity of the ribonucleoprotein complex vRNP, wherein loci at which the dendrobine is combined with influenza virus NP proteins are Arg267 at locus 267, Val270 at locus 270, Phe338 at locus 338 and Glu339 at locus 339.

The invention discloses application of myricetin in the preparation of anti-influenza-virus drugs. Influenza A virus is referred to herein, preferably, H1N1, H3N2, H5N1, H7N1, H7N2, H7N3, H7N7, H7N9,H9N2 or H10N8. The acting mechanism of myricetin to resist influenza A virus is to inhibit activity of ribonucleoprotein complex vRNP by combination with PB2cap protein; myricetin is applicable to thepreparation of drugs to prevent and treat influenza viruses, wherein sites of myricetin combined with influenza virus PB2cap protein are histidine at 357 (His357), phenylalanine at 404 (Phe404), phenylalanine at 323 (Phe323), glutamic acid at 361 (Glu361), lysine at 376 (Lys376), phenylalanine at 363 (Phe363) and asparagine at 429 (Asn429).

The invention discloses an application of enilconazole in preparing a drug for treating or preventing influenza virus infections. Firstly, toxicity of enilconazole to MDCK cells is detected. The result shows that the maximum non-toxic concentration of enilconazole is 100.0 [mu]M. Secondly, antiviral activity of enilconazole is measured within a completely non-toxic concentration range. The result shows that the small molecular compound has significant antiviral activity and the antiviral activity presents a dosage-dependent effect. Finally, the antiviral activities of enilconazole to influenza viruses in different types and subtypes are detected. The results show that enilconazole can suppress replication of all the detected influenza virus strains in a dose-dependent manner, so that the anti-influenza virus activity of enilconazole has a broad spectrum. Therefore, enilconazole disclosed by the invention is a novel broad-spectrum anti-influenza virus drug and can be used for preparing the drug for treating or preventing the influenza virus infections.

The invention discloses a racemic and chiral 3-(2, 3-butadienyl)oxoindolone compound, a method for preparing the compound by adopting a palladium-catalyzed coupling reaction, and application of the compound. According to the method, 2, 3-butadienyl carbonate and oxoindolone react in an organic solvent in the presence of a palladium catalyst to directly construct the racemic 3-(2, 3-butadienyl)oxoindolone compound in one step. If the palladium catalyst and the chiral phosphine ligand are used in a system and react in then organic solvent, the chiral 3-(2, 3-butadienyl)oxoindolone compound can be directly constructed in one step, and the compound can be easily converted into other complex molecules. The method is convenient to operate, raw materials and reagents are easy to obtain, the substrate universality is wide, the functional group compatibility is good, and the reaction has good conversion rate and high enantioselectivity and chemical selectivity. Besides, the 3-(2, 3-butadienyl)oxoindolone compound and related derivatives thereof provided by the invention can be combined with SRAS-CoV-2 main protein 3CL hydrolase, and have a good application prospect in the aspect of treating human virus infection.

The invention discloses an application of diphenhydramine hydrochloride in preparation of medicines for treating or preventing influenza viruses. Firstly, diphenhydramine hydrochloride with completely nontoxic concentration is selected for an antiviral test, and the result shows that the small molecular compound has remarkable antiviral activity and is in dose-dependent association; then, the action period of diphenhydramine hydrochloride which resists influenza viruses is analyzed, and the result shows that diphenhydramine hydrochloride mainly inhibits events in early stage of virus infection such as virus absorption and entrance; and finally, the antiviral activity of diphenhydramine hydrochloride to different types and sub-types of influenza viruses is detected, and the result shows that diphenhydramine hydrochloride can inhibit replication of all detection viral strains and has the dose-dependent effect, thereby representing that diphenhydramine hydrochloride is of certain broad spectrum to anti-influenza virus activity. The diphenhydramine hydrochloride disclosed by the invention can be developed as a novel anti-influenza virus medicine and provides a novel path and means for treating influenza.

The present invention relates to an antiviral bacteria-killing cleaning detergent with several health-care functions. Said cleaning detergent is made up by using the raw materials of water, edible acetin, edible vinegar, garlic, onion, clove, cinnamon bark, nutmeg, origanum, hot pepper, grape, thymus mongolicus, gleditsia fruit and sorbate through a traditional preparation process. Said invention also provides its application range.

The invention discloses a lactalbumin-oleic acid compound and carrageenan composite medicine, which consists of 0.01-1 part by weight of a lactalbumin-oleic acid compound, 0.5-1.5 parts by weight of carrageenan, 1-3 parts by weight of carbomer, 1-5 parts by weight of glycerol and 0.1-0.2 part by weight of ethylparaben. The composite medicine is in the form of a gel, a suppository or a dressing. The composite medicine can be used for preventing and treating female human papilloma virus infection as well as for preventing and treating female gynecological gram negative bacterium infection.

The invention discloses application of GW3965 (3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2, 2)-biphenylethyl)amino]propoxy)phenylacetate hydrochloride) in preparation of drugs treating or preventing hepatitis C virus. A drug without any toxic concentration is chosen for an antiviral experiment, the influence of GW3965 on virus gene duplication is detected, and results show that the small molecule compound has significant antiviral activity and is dose dependent. Then, the GW3965 is employed to treat the hepatitis C pseudovirus system of different gene subtypes, and results show that the compound inhibits the virus entrance link at the early stage of a virus lifecycle. The anti-virus capability of drug combination of GW3965 and other anti-HCV drugs is detected, and results show that the compound has the potential of drug combination with other drugs. GW3965 can inhibit 1a, 1b, and 2a genotype virus entrance, and has broad-spectrum antiviral activity and a novel target, while there is no anti-hepatitis C virus drug with entrance as the target clinically. And drug combination can achieve a good effect.

The invention discloses application of a cellular target liver X receptor in preparation of drugs treating hepatitis C virus (HCV), specifically a cellular target that can be used for screening anti-HCV drugs. The cellular target is a liver X receptor (LXR). The agonist GW3965 and T0901317 of the liver X receptor have significant anti-hepatitis C activity in invitro anti-hepatitis C virus experiments. The cellular target liver X receptor can be used for screening drugs treating the hepatitis C virus. Therefore, the cellular target LXR involved in the invention can be applied to drug development as a new anti-hepatitis C virus target, thus providing a new approach and means for treatment and cure of hepatitis C.

The invention relates to a chickweed polysaccharide composition and applications thereof in preparation of an antiviral medicine. The chickweed polysaccharide composition disclosed by the invention is prepared by mixing five kinds of chickweed polysaccharides (A, B, C, D and E) according to a certain proportion and is characterized in that the composition is of brown floccule which is easily dissolved in water and is not dissolved in ethanol, acetone, diethyl ether, n-butanol and isopropanol with high concentration; the polysaccharide composition contains five kinds of chickweed polysaccharides with molecular weights ranging from 5000 to 30000 and is formed by rhamnose, arabinose, xylose, mannose, glucose and galactose according to certain molar ratio. After being mixed uniformly in a special proportion, the five kinds of the polysaccharides can be used for strengthening antiviral activities by utilizing mutual synergy. The invention further discloses a use of the chickweed polysaccharide composition in preparation of the antiviral medicine, which is used for treating the diseases such as hepatitis B virus, HIV (human immunodeficiency virus), herpes virus, influenza virus, enterovirus and adenovirus and the like and can be prepared into various pharmaceutic preparations. The composition has a good therapeutic effect, no toxicity and wide prospect in development of new antiviral medicines.

The invention discloses application of doxylamine succinate in preparing a drug for treating or preventing influenza virus. The application comprises the following steps of: selecting the doxylamine succinate with complete non-toxic concentration to carry out antiviral experiment, wherein the result shows that the micromolecule compound has remarkable antiviral activity and is dose-dependent; and detecting the antiviral activity of the doxylamine succinate to different types and subtypes of influenza viruses, wherein the result indicates that the doxylamine succinate has activity for detecting virus strain, a dose-dependent effect, as well as a certain broad-spectrum to the anti-influenza virus activity. Therefore, the doxylamine succinate disclosed by the invention can be developed as a novel anti-influenza virus drug, so that a novel way and means is provided for treating the influenza.

The invention relates to the technical field of medicines and particularly discloses an application of diethylstilbestrol to preparation of a medicine for treating or preventing influenza virus infection. Firstly, the toxicity of diethylstilbestrol to an MDCK (madin darby canine kidney) cell is detected to obtain a result which shows that the maximum non-cytotoxic concentration of diethylstilbestrol is 25.0muM; secondly, the antiviral activity of diethylstilbestrol is detected within a complete non-cytotoxic concentration range to obtain a result which shows that the small-molecular compound has remarkable antiviral activity and the antiviral effect has a dose-dependent effect; finally, the antiviral activity of diethylstilbestrol to different types and subtypes of influenza viruses is detected to obtain a result which shows that diethylstilbestrol can inhibit the replication of all the detected influenza virus strains in a dose-dependent way, so that the anti-influenza virus activity of diethylstilbestrol is proved to have broad spectrum. Therefore, the invention firstly discloses diethylstilbestrol as a novel broad-spectrum anti-influenza virus medicine which can be used for preparing a medicine for preventing or treating influenza virus infection.

The invention discloses application of nafronyloxalate in preparing a medicine for preventing or treating influenza virus. According to the application, first, the cytotoxicity of nafronyloxalate to MDCK (madin-darby canine kidney) cells is detected, and results indicate that CC50 (50% cytotoxic concentration) of the nafronyloxalate is 238.1mu M; secondly, nafronyloxalate with non-cytotoxic concentration is selected to be subjected to anti-virus experiments, and results indicate that the small molecular compound has a remarkable anti-virus activity and is related to dose dependence; finally, the anti-virus activity of the nafronyloxalate to different types and sub-type influenza viruses is detected, and results indicate that nafronyloxalate can be used for inhibiting replication of all detected virus strains and has a dose dependent effect, and the anti-virus activity of the nafronyloxalate has a certain broad-spectrum. Therefore, the nafronyloxalate can be used as a novel anti-virus medicine for developing, and a novel way and means is provided to influenza treatment.

An antiviral bactericiding liquid detergent is prepared from water, sodium benzoate, edible vinegar and its essence, garlic clove, onion and 8 Chinese-medicinal materials including cloves, cinammon bark, etc. Its advantages are broad bactericiding spectrum, high detergency, and high effect to prevent cold and infectious disease and improve human immunity.